Kadmon Acquires FDA Approval For Belumosudil

Chronic Graft-Versus-Host Disease Gets a New Treatment: Belumosudil

  • Belumosudil got FDA Approval on July 16, 2021, to treat Chronic Graft-Versus-Host Disease (chronic GVHD).
  • Eligible patients must be aged at least 12 years and have received two prior systemic therapies.

Patients suffering from Chronic Graft-Versus-Host Disease now have an efficacious treatment option, Belumosudil. On 16th July 2021, US FDA (Food and Drug Administration) approved Belumosudil (marketed by Kadmon Pharmaceuticals LLC under the brand name Rezurock) for the treatment of t...

cancer medicine, new medicine, new research,